ATYR - NASDAQ
aTyr Pharma, Inc.
$0.54
+5.8%aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
At a Glance
Live Snapshotatyr
Shares Outstanding
Last Annual Value
92.99M
3-Year CAGR
48%
5-Year CAGR
59%
10-Year CAGR
55%
aTyr Pharma, Inc. Competitors Analysis of shares-outstanding
| Company | shares-outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
aTyr Pharma, Inc. NASDAQ:ATYR | 92.99M | 20.2% | 37.3% | 49.3% | |
 MindWalk Holdings Corp. NASDAQ:HYFT | 33.38M | 10.3% | 15.2% | 32.5% | |
 Metagenomi, Inc. Common Stock NASDAQ:MGX | 37.25M | -0.2% | 44.4% | N/A | |
 MacroGenics, Inc. NASDAQ:MGNX | 63.16M | 0.7% | 1.0% | 6.2% | |
 Adverum Biotechnologies, Inc. NASDAQ:ADVM | 19.78M | -30.1% | -27.4% | -5.9% | |
 Surrozen, Inc. NASDAQ:SRZN | 7.48M | 54.7% | 26.2% | N/A | |
 Biomea Fusion, Inc. NASDAQ:BMEA | 52.23M | 15.3% | 17.0% | N/A | |
 Fractyl Health, Inc. Common Stock NASDAQ:GUTS | 75.82M | 16.8% | 9.8% | N/A | |
 Kalaris Therapeutics Inc NASDAQ:KLRS | 15.27M | 50.0% | 41.1% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 766.60K | 15.3% | 4.8% | N/A | |
 Unicycive Therapeutics, Inc. NASDAQ:UNCY | 158.87M | 301.5% | 167.1% | N/A |
aTyr Pharma, Inc. Fair Value Envelope
Related Guides
Continue your ATYR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.